Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Berntorp

Showing results (31-40 of 250) with videos related to

Pageof 25
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 8, 2009
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimensE Berntorp
Vox Sanguinis|January 1, 1996
Why prescribe highly purified factor VIII and IX concentrates?E Berntorp
Journal of Thrombosis and Haemostasis : JTH|March 25, 2017
If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophiliaE Berntorp
Journal of Internal Medicine|May 21, 2016
Future of haemophilia outcome assessment: registries are key to optimized treatmentE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 18, 2018
Replacement therapy during surgery in von Willebrand disease needs personalizationE Berntorp
Diabetologia|May 13, 2016
Gestational diabetes: what's up?Kerstin E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 28, 2003
The pharmacokinetics of clotting factor therapyE Berntorp, S Björkman
Journal of Thrombosis and Haemostasis : JTH|October 25, 2006
The von Willebrand disease prophylaxis network: exploring a treatment conceptE Berntorp, T Abshire,
Journal of Internal Medicine|March 22, 2016
Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidenceM Osooli, E Berntorp
European Journal of Haematology|January 1, 1987
(3H)ouabain binding to leukaemic cells and intralymphocytic sodium content in chronic lymphocytic leukaemia; no evidence for alterations of the Na+/K+-pumpE Berntorp, K Berntorp
Pageof 25

Showing results (31-40 of 250) with videos related to

Sort By:
Pageof 25
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 8, 2009
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimensE Berntorp
Vox Sanguinis|January 1, 1996
Why prescribe highly purified factor VIII and IX concentrates?E Berntorp
Journal of Thrombosis and Haemostasis : JTH|March 25, 2017
If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophiliaE Berntorp
Journal of Internal Medicine|May 21, 2016
Future of haemophilia outcome assessment: registries are key to optimized treatmentE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 18, 2018
Replacement therapy during surgery in von Willebrand disease needs personalizationE Berntorp
Diabetologia|May 13, 2016
Gestational diabetes: what's up?Kerstin E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 28, 2003
The pharmacokinetics of clotting factor therapyE Berntorp, S Björkman
Journal of Thrombosis and Haemostasis : JTH|October 25, 2006
The von Willebrand disease prophylaxis network: exploring a treatment conceptE Berntorp, T Abshire,
Journal of Internal Medicine|March 22, 2016
Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidenceM Osooli, E Berntorp
European Journal of Haematology|January 1, 1987
(3H)ouabain binding to leukaemic cells and intralymphocytic sodium content in chronic lymphocytic leukaemia; no evidence for alterations of the Na+/K+-pumpE Berntorp, K Berntorp
Pageof 25